|
|
||||||||
expression modulates muscle glucose uptake through an insulin receptor/Akt-independent, AMPK-dependent pathway
Departments of Internal Medicine and Clinical Pathology, State University of Campinas, Campinas-SP 13083-970, Brazil
Submitted 3 March 2004 ; accepted in final form 21 May 2004
| ABSTRACT |
|---|
|
|
|---|
coactivator-1
(PGC-1
) participates in control of expression of genes involved in adaptive thermogenesis, muscle fiber type differentiation, and fuel homeostasis. The objective of the present study was to evaluate the participation of cold-induced PGC-1
expression in muscle fiber type-specific activity of proteins that belong to the insulin-signaling pathway. Rats were exposed to 4°C for 4 days and acutely treated with insulin in the presence or absence of an antisense oligonucleotide to PGC-1
. Cold exposure promoted a significant increase of PGC-1
and uncoupling protein-3 protein expression in type I and type II fibers of gastrocnemius muscle. In addition, cold exposure led to higher glucose uptake during a hyperinsulinemic clamp, which was accompanied by higher expression and membrane localization of GLUT4 in both muscle fiber types. Cold exposure promoted significantly lower insulin-induced tyrosine phosphorylation of the insulin receptor (IR) and Ser473 phosphorylation of acute transforming retrovirus thymoma (Akt) and an insulin-independent increase of Thr172 phosphorylation of adenosine 5'-monophosphate-activated protein kinase (AMPK). Inhibition of PGC-1
expression in cold-exposed rats by antisense oligonucleotide treatment diminished glucose clearance rates during a hyperinsulinemic clamp and reduced expression and membrane localization of GLUT4. Reduction of PGC-1
expression resulted in no modification of insulin-induced tyrosine phosphorylation of the IR and Ser473 phosphorylation of Akt. Finally, reduction of PGC-1
resulted in lower Thr172 phosphorylation of AMPK. Thus cold-induced hyperexpression of PGC-1
participates in control of skeletal muscle glucose uptake through a mechanism that controls GLUT4 expression and subcellular localization independent of the IR and Akt activities but dependent on AMPK. acute transforming retrovirus thymoma; adenosine 5'-monophosphate-activated protein kinase; cold exposure
(PPAR
) coactivator-1
(PGC-1
) is a 795-amino acid protein with a molecular mass of 92 kDa. It has been identified in brown adipose tissue and skeletal muscle through a yeast two-hybrid system on the basis of its properties of induction by cold and binding to PPAR
(31). As a transcriptional coactivator, PGC-1
possesses several functional domains that participate in protein-protein interaction (30). Motifs that allow for interaction with PPAR
(31), nuclear respiratory factor (48), cAMP response element binding protein-binding protein (16), steroid receptor coactivator-1 (5), and myocyte enhancer factor-2 (22), have been identified and are thought to participate in the PGC-1
-dependent regulation of expression of genes involved in an array of specialized cell functions, such as the response to environmental thermal oscillations (31), mitochondrial biogenesis (31, 48), energy and nutrient homeostasis (27), muscle fiber type differentiation (19), adipocyte differentiation (31), cellular response to cytokines (29), and control of insulin secretion (7, 49).
Recent studies have implicated PGC-1
expression as a mechanism involved in the control of glucose uptake and insulin sensitivity in muscle cells (22). Accordingly, at least two clinical studies have found a correlation between mutations of the PGC-1
gene and insulin resistance or diabetes (8, 13). The mechanisms by which PGC-1
may regulate glucose uptake and insulin action are not completely understood. Hyperexpression of PGC-1
in muscle cells significantly induces the expression of glucose transporter-4 (GLUT4), but this seems to be an insulin-independent process (22). On the other hand, PGC-1
expression is upregulated by endurance training and by chronic treatment with the AMP-activated protein kinase (AMPK) agonist 5-aminoimidazole-4-carboxamide-1-
-D-ribofuranoside, which lead to increased glucose uptake through insulin-independent mechanisms (1, 38).
The exposure of homeothermic animals to a cold environment has been widely used as a model for studying glucose homeostasis and insulin action (11, 45). Under this condition, animals mobilize glucose more efficiently, despite molecular resistance to insulin signal transduction in skeletal muscle and adipose tissue (11). Because cold exposure significantly induces PGC-1
expression in muscle, we decided to evaluate the effect of PGC-1
expression inhibition on glucose clearance and insulin signal transduction in type I and type II fiber-rich portions of gastrocnemius muscle from control and cold-exposed Wistar rats.
| MATERIALS AND METHODS |
|---|
|
|
|---|
-D-arabinofuranoside (ARA-A) from Sigma (St. Louis, MO); protein A-Sepharose 6MB from Pharmacia (Uppsala, Sweden),125I-protein A, [U-14C]sucrose, and 2-deoxy-D-[3H]glucose (2-DG) from ICN Biomedicals (Costa Mesa, CA); nitrocellulose paper (BA85, 0.2 µm) from Amersham (Aylesbury, UK); and thiopental sodium and human recombinant insulin (Humulin R) from Lilly (Indianapolis, IN). Polyclonal antiphosphotyrosine antibodies were raised in rabbits and affinity purified on phosphotyramine columns. Anti-insulin receptor (IR; rabbit polyclonal, catalog no. sc-711), anti-GLUT4 (goat polyclonal, catalog no. sc-1608), anti-GLUT-1 (rabbit polyclonal, catalog no. sc-7903), antiphospho-ERK (
-pERK/Tyr204, detecting pERK42 and pERK44; goat polyclonal, catalog no. sc-7976), anti-phospho-Ser473 Akt (rabbit polyclonal, catalog no. sc-7985-R), anti-uncoupling protein (UCP)-3 (goat polyclonal, catalog no. sc-7756), and anti-PGC-1
(goat polyclonal, catalog no. sc-5816) antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA) and antiphospho-Thr172 AMPK-
(rabbit polyclonal, catalog no. 2531) and anti-AMPK-
(rabbit polyclonal, catalog no. 2532) from Cell Signaling Technology (Beverly, MA). Enzymatic colorimetric assay for the quantification of nonesterified fatty acids was obtained from Wako Chemicals (Richmond, VA), the leptin detection kit from Linco Research (St. Charles, MO), and corticosterone and thyroid-stimulating hormone RIA kits from Amersham Pharmacia Biotech-BIOTRAK (Aylesbury, UK). Insulin was determined by RIA (37). Experimental animals and cold exposure protocols. Male Wistar rats (Rattus norvegicus; 8 wk old, 200300 g body wt) were obtained from the University of Campinas Animal Breeding Center. The investigation followed the State University of Campinas guidelines for the use of animals in experimental studies and conforms to the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1996). The animals were maintained on a 12:12-h artificial light-dark cycle and housed in individual cages. After the acclimatizing period (3 days), the animals were randomly divided into two groups: cold-exposed animals (4 ± 1°C for 4 days) and thermoneutrality-maintained (control) animals (23 ± 1°C). The animals were allowed free access to standard rodent chow and water. For tissue extraction (on day 4 of the experimental protocol), rats were anesthetized with thiopental sodium (15 mg/kg body wt ip), and the experiments were performed after the loss of corneal and pedal reflexes. After experimental procedures, the rats were euthanized under anesthesia following the recommendations of NIH Publication No. 85-23.
Metabolic, hormone, and biochemical measurements. Food intake, rectal temperature, and body weight (during the light cycle) were measured at time 0, 2 h from the beginning of the experimental period, and daily during the 4 experimental days in control and cold-exposed rats. Rectal temperature was measured with a high-precision digital thermometer (Hanna Instruments, Woonsocket, RI) inserted 1.5 cm from the anus. In rats treated with sense or antisense oligonucleotides, 24-h food intake and body temperature were determined and compared with controls. Blood samples were obtained from rats fasted for 2 h. Plasma glucose was measured by the glucose oxidase method in samples collected from the tail at time 0, 2 h, and daily (42). Nonesterified fatty acid was determined by ELISA according to the manufacturer's directions in samples collected at time 0 and 2 h and on days 2 and 4. Insulin was detected by RIA with a guinea pig anti-rat insulin antibody and rat insulin as standard (37) on samples collected at time 0 and 2 h and on days 2 and 4. Serum leptin concentrations were measured by ELISA on samples collected at time 0 and 2 h and on days 2 and 4. Corticosterone and thyroid-stimulating hormone were measured by RIA according to the manufacturer's specifications on samples collected at time 0 and 2 h and on days 2 and 4. Plasma norepinephrine levels here determined by reverse-phase HPLC according to a method previously described (4). Samples were collected at the end of the experimental period.
2-DG studies. Tissue uptake of 2-DG was measured in vivo according to a method described previously (44) with minor modifications (11). The rats were anesthetized and then injected through the portal vein with 6.0 µCi of 2-DG and [14C]sucrose in the presence or absence of 0.1 U of insulin in 0.4 ml of isotonic phosphate buffer (pH 7.4) with 0.1% defatted BSA. After 16 min, slices of gastrocnemius muscle tissue were quickly removed and solubilized in NCS-II tissue solubilizer (Amersham, Buckinghamshire, UK). The radioactivity of 3H in the resulting supernatant was measured in liquid scintillation fluid (ACS-II, Amersham, Tokyo, Japan) using a scintillation counter (model LSC-1000, Aloka, Kyoto, Japan). Cellular uptake of 2-DG was calculated as the difference between the total tissue radioactivity and the amount of radioactivity in the tissue extracellular space. The extracellular space volume (in µl/mg) was calculated by dividing the amount of 14C (dpm/mg) in tissue by the amount of 14C (dpm/µl) in plasma. The concentration of extracellular 3H (dpm/mg) in tissue could then be obtained by multiplying the extracellular volume (in µl/mg) of tissue by the concentration of 3H (dpm/µl) in plasma. The cellular radioactivity was converted to picomoles of 2-DG using the specific activity, and the results were expressed per milligram of dry tissue.
Mitochondrial respiration rates and phosphorylation efficiency.
Muscle mitochondria were isolated from rat hindlimb skeletal muscle by homogenization in ice-cold medium containing 100 mM sucrose, 100 mM KCl, 50 mM Tris·HCl, 1 mM K2HPO4, 0.1 mM EGTA, and 0.2% BSA (pH 7.4) followed by differential centrifugation (40). The final mitochondrial pellet was resuspended in ice-cold storage buffer containing 0.2 M mannitol, 0.1 M sucrose, 10 mM Tris·HCl, and 0.1 mM EDTA (pH 7.4). The presence of fatty acid-free 0.2% BSA in the buffers throughout the isolation procedure depleted the mitochondria of endogenous free-fatty acids. Oxygen consumption was measured using a Clark-type electrode (Hansatech Instruments; OXIGRAPH software, version 1.10) in a 0.5-ml glass chamber equipped with magnetic stirring. Mitochondria (0.5 mg/ml) from type I and type II fiber-rich gastrocnemius muscle were added to the standard medium containing 225 mM mannitol, 75 mM sucrose, 10 mM Tris·HCl (pH 7.4), 10 mM KH2PO4, and 0.1 mM EDTA at 28°C. Respiration rates are given in nanomoles of oxygen per milligram per minute. Phosphorylating (state 3) respiration was initiated by addition of 100 nmol ADP/mg protein. Phosphorylation efficiency (ADP-to-O ratio) was calculated from the added amount of ADP and the total amount of oxygen consumed during state 3. Preparations were treated with NAD-linked substrates,
-ketoglutarate, pyruvate, malate, and glutamate at 5 mM and with 1 µM carboxyatractiloside, 6 µM linoleic acid, 500 µM GDP, and 0.1% BSA.
Clamp studies.
All procedures for clamp studies followed a previously published description of the method (2, 6). After 6 h of fasting, a 2-h hyperinsulinemic-euglycemic clamp study was performed in the lower limb. Under thiopental sodium anesthesia and aseptic conditions, a monoocclusive polyethylene catheter was inserted into the femoral artery for infusion of insulin and glucose. A second polyvinyl catheter was inserted into the femoral vein for blood sampling, and the animal was kept in a heated box (37°C) throughout the study. During the first phase of the study (30 min), a priming dose of insulin was infused followed glucose infusion at a rate necessary to reach a plateau. After glucose equilibration, insulin infusion (3.0 mU·kg2·min1) was maintained for 2 h at a constant rate (0.20 ml/h), and a variable infusion of glucose (5% solution) was adjusted to maintain the plasma glucose concentration at
120 mg/dl. Blood samples were collected from the femoral vein every 5 min for plasma glucose and every 30 min for plasma insulin determinations. Insulin was measured in duplicate by RIA and oscillated between 4.0 and 9.0 ng/ml in samples collected from animals of both experimental groups.
Sense and antisense oligonucleotide treatment protocols.
Sense and antisense oligonucleotides (Invitrogen, Carlsbad, CA) were diluted to a final concentration of 20 µmol/l in dilution buffer containing 10 mmol/l Tris·HCl and 1 mmol/l EDTA. The rats were injected intraperitoneally with two doses (24 h and 4 h before the experimental procedure) of 200 µl of dilution buffer with or without sense or antisense oligonucleotides. Phosphothioate-modified oligonucleotides were designed according to the R. norvegicus PGC-1
sequence deposited at the National Center for Biotechnology Information under the designation NM 031347 and were composed of sense (5'-TCA GGA GCT GGA TGG C-3') and antisense (5'-GCC ATC CAG CTC CTG A-3'). These oligonucleotides have been tested previously, and the antisense was capable of reducing the expression of PGC-1
by
60% in pancreatic islets (7). In the present studies, we have employed Western blot analyses of total protein extracts from muscle to evaluate PGC-1
protein expression in control and sense and antisense oligonucleotide-treated rats. We also evaluated UCP-3 expression by Western blot and mitochondrial respiration in muscle from rats of the same experimental groups.
ARA-A in vivo treatment protocol. In some experiments, rats were treated with the AMPK inhibitor ARA-A. The drug (25 mmol/dose) was injected intraperitoneally 12 and 2 h before the experimental procedure (25).
Semiquantitative RT-PCR.
Seven micrograms of total RNA from type I or type II fiber-rich portions of the gastrocnemius muscle of rats exposed to cold for 4 days or unexposed rats were reverse transcribed with SuperScript RT (200 U/µl) using 50 mM oligo(dT) in a 30-µl reaction volume (5x RT buffer, 10 mM dNTP, and 40 U/µl RNase-free inhibitor). The reverse transcriptions consisted of incubation for 50 min at 42°C and incubation for 15 min at 70°C. After reverse transcription, 0.75 µl of the RT products were used in each PCR at a final volume of 50 µl (10x PCR buffer, 1.0 mM dNTP, 50 mM MgCl2, Taq polymerase, and sense and antisense primers for PGC-1
and
-actin). The expression of mRNA was determined by PCR using the primers 5'-TTT GGG AGG GTG AGG GAC TCC-3' (antisense) and 5'-TGA GCG CAA GTA CTC TGT GTG G-3' (sense), amplifying a 489-bp DNA fragment of
-actin, and the primers 5'-GGA TCT TGA AGA GGA TCT AC-3' (antisense) and 5'-TGA GTG TTC TGG TAC CCA AG-3' (sense), amplifying a 804-bp DNA fragment of PGC-1
. Triplicate reactions were performed using an initial incubation at 94°C for 5 min and denaturation at 94°C for 1 min followed by annealing at 50°C and 57°C (for PGC-1
and
-actin, respectively) for 50 s, extension at 72°C for 1 min, and final extension at 72°C for 7 min. Titration between 16 and 32 cycles revealed that 25 cycles for
-actin and 35 cycles for PGC-1
were within the logarithmic phase of amplification. These PCR conditions were therefore used in subsequent experiments. All PCR experiments included a control tube with no RT step. PCR-amplified products were run on 2% Tris-acetic acid-EDTA-agarose gels, and the DNA was visualized by ethidium bromide staining. The size of the products was determined using a 1-kb plus DNA ladder (Life Technologies) as standard size markers. Images of the bands were captured using a UV transluminator (TFX 35M, Life Technologies), and band intensity was quantified by digital densitometry (Scion Image software).
Tissue extraction, immunoblotting, and immunoprecipitation.
The abdominal cavities of anesthetized rats were opened, and the experimental animals received an infusion of insulin (0.2 ml, 106 M) or saline (0.2 ml) through the cava vein. After different intervals (see RESULTS), fragments (4.0 x 4.0 x 4.0 mm) of type I or type II fiber-rich portions of gastrocnemius muscle were excised and immediately homogenized in solubilization buffer at 4°C [1% Triton X-100, 100 mM Tris·HCl (pH 7.4), 100 mM sodium pyrophosphate, 100 mM sodium fluoride, 10 mM EDTA, 10 mM sodium orthovanadate, 2.0 mM PMSF, and 0.1 mg aprotinin/ml] with a Polytron PTA 20S generator (model PT 10/35; Brinkmann Instruments, Westbury, NY) operated at maximum speed for 30 s. Insoluble material was removed by centrifugation for 20 min at 9,000 g in a 70.Ti rotor (Beckman) at 4°C. The protein concentration of the supernatants was determined by the Bradford dye-binding method. Aliquots of the resulting supernatants containing 5.0 mg of total protein were used for immunoprecipitation with antibodies against IR at 4°C overnight followed by SDS-PAGE, transfer to nitrocellulose membranes, and blotting with antiphosphotyrosine or anti-IR antibodies. In direct immunoblot experiments, 0.2 mg of protein extracts from each tissue was separated by SDS-PAGE, transferred to nitrocellulose membranes, and blotted with anti-IR, antiphospho-Akt, antiphospho-ERK, anti-GLUT4, anti-GLUT-1, anti-PGC-1
, anti-UCP-3, antiphospho-AMPK, and antiphosphoacetyl-CoA carboxylase antibodies, as described previously (3).
Subcellular fractionation. To characterize the expression and subcellular localization of GLUT4, a subcellular fractionation protocol was employed as described previously (24) with minor modifications. Fragments of type I or type II fiber-rich portions of gastrocnemius muscle from untreated rats or rats treated with insulin (0.2 ml, 106 M, tissue obtained 15 min after insulin infusion) according to the protocols described above were minced and homogenized in 2 vol of STE buffer [0.32 M sucrose, 20 mM Tris·HCl (pH 7.4), 2 mM EDTA, 1 mM DTT, 100 mM sodium fluoride, 100 mM sodium pyrophosphate, 10 mM sodium orthovanadate, 1 mM PMSF, and 0.1 mg aprotinin/ml] at 4°C with a Polytron homogenizer. The homogenates were centrifuged (1,000 g, 25 min, 4°C) to obtain pellets. The pellets were washed once with STE buffer (1,000 g, 10 min, 4°C) and suspended in Triton buffer [1% Triton X-100, 20 mM Tris·HCl (pH 7.4), 150 mM NaCl, 200 mM EDTA, 10 mM sodium orthovanadate, 1 mM PMSF, 100 mM NaF, 100 mM sodium pyrophosphate, and 0.1 mg aprotinin/ml], kept on ice for 30 min, and centrifuged (15,000 g, 30 min, 4°C) to obtain the nuclear fraction. The supernatant was centrifuged (100,000 g, 60 min, 4°C) to obtain the cytosol fraction and the pellet, which was suspended in STE buffer + 1% NP-40, kept on ice for 20 min, and centrifuged (100,000 g, 20 min) to obtain the membrane fraction. The fractions were treated with Laemmli buffer with 100 mM DTT and heated in a boiling water bath for 5 min, and aliquots (0.2 mg of protein) were subjected to SDS-PAGE and Western blotting with anti-GLUT4 antibodies, as described elsewhere (11).
Data presentation and statistical analysis. Values are means ± SE of the indicated number of experiments. The results of blots are presented as direct comparisons of bands in autoradiographs and quantified by densitometry using Scion Image software (ScionCorp). Student's t-test for unpaired samples and ANOVA for multiple comparisons were used for statistical analysis as appropriate. The post hoc test was employed when required. The level of significance was set at P < 0.05.
| RESULTS |
|---|
|
|
|---|
|
and UCP-3 in muscle.
The concentrations of PGC-1
and UCP-3 were determined in total protein extracts of type II and type I fiber-rich portions of gastrocnemius muscle from cold-exposed and control rats. The extracts were subjected to SDS-PAGE, transferred to nitrocellulose membrane, and blotted with specific antibodies. Cold exposure induced increases of 1.5-fold (P < 0.05) and 2.8-fold (P < 0.05) in PGC-1
expression in type II (Fig. 1A)and type I (Fig. 1B) fibers, respectively. Similarly, cold exposure induced 4.3-fold (P < 0.05) and 4.6-fold (P < 0.05) increases in UCP-3 expression in type II (Fig. 1A) and type I (Fig. 1B) fibers, respectively. Cold-induced hyperexpression of PGC-1
in both fiber types was also evident at the mRNA level, as detected by RT-PCR (Fig. 1C): 2.1-fold (P < 0.05) and 5.3-fold (P < 0.05) increase of PGC-1
in type II and type I fibers, respectively.
|
protein expression in muscle.
Because the objective of the present study was to evaluate the possible involvement of PGC-1
in insulin signal transduction, we decided to look first for any possible effect of an acute dose of insulin on the expression of PGC-1
. Control and cold-exposed rats were injected with a single intravenous (through the vena cava) dose of saline with or without insulin (200 µl, 106 M), and after 10 min, fragments of type I and type II fiber-rich portions of gastrocnemius muscle were excised, homogenized, and subjected to SDS-PAGE, transferred to nitrocellulose membranes, and blotted with PGC-1
-specific antibodies. An acute dose of insulin promoted no significant changes in PGC-1
expression in either type of muscle fiber (Fig. 2).
|
|
|
protein expression reduction inhibits glucose uptake in cold-exposed rats.
To evaluate the participation of cold-induced PGC-1
expression on insulin signal transduction in skeletal muscle, control and cold-exposed rats were treated (4.0 nmol) with antisense or sense (not shown) phosphorthioate-modified oligonucleotides specific for PGC-1
, in parallel with rats not treated with oligonucleotide. The treatment with sense or antisense oligonucleotide did not modulate 24-h food intake and body temperature (not shown). Initially, the blocking capacity of the oligonucleotide was evaluated by immunoblot of SDS-PAGE-separated, nitrocellulose-transferred proteins extracted from type I and type II fiber-rich portions of gastrocnemius muscle. PGC-1
antisense treatment led to significant reduction of basal [control; 0.3-fold (P < 0.05) and 0.15-fold (P < 0.05)] and cold-induced [0.2-fold (P < 0.05) and 0.1-fold (P < 0.05)] PGC-1
protein expression in type II (Fig. 5A)and type I (Fig. 5B) fiber-rich portions of gastrocnemius muscle, respectively. This was accompanied by significant reduction of cold-induced [0.5-fold (P < 0.05) and 0.65-fold (P < 0.05) for type II and type I fiber-rich portions of gastrocnemius, respectively], but not basal, UCP-3 expression in both fiber types (Fig. 5, A and B). To further evaluate the effect of PGC-1
blockade on UCP-3, a mitochondrial respiration assay was performed (Fig. 5, C and D). The quality of mitochondria preparation was optimal, presenting ADP-to-O ratios of 2.9 ± 0.2, 2.9 ± 0.1, 2.8 ± 0.2, and 2.9 ± 0.1 for mitochondria from type II muscle without oligonucleotide, type II muscle with PGC-1
antisense oligonucleotide, type I muscle without oligonucleotide, and type I muscle with PGC-1
antisense oligonucleotide, respectively, and respiratory control (state 3-to-state 4 ratio) of 4.87 ± 1.26, 4.37 ± 0.32, 4.46 ± 0.46, and 4.38 ± 0.39 for mitochondria from type II muscle without oligonucleotide, type II muscle with PGC-1
antisense oligonucleotide, type I muscle without oligonucleotide, and type I muscle with PGC-1
antisense oligonucleotide, respectively. The blockade of PGC-1
expression resulted in improved mitochondrial respiratory coupling in type II, but not type I, fiber-rich portions of gastrocnemius muscle, because the post/prelinoleic acid oxygen consumption rate ratio was 2.2 for mitochondria from the type II fiber-rich portion of the gastrocnemius not treated with oligonucleotide and 1.4 for mitochondria from the type II fiber-rich portion of the gastrocnemius treated with PGC-1
antisense oligonucleotide (Fig. 5, C and D).
|
blockade on insulin-induced glucose uptake, cold-exposed and control rats were treated with PGC-1
antisense oligonucleotide and subjected to a hyperinsulinemic-euglycemic clamp. Cold exposure induced a significant increase (4.8-fold, P < 0.05) of insulin-induced glucose consumption (Fig. 6),which was reversed by the blockade of PGC-1
(0.6-fold, P < 0.05). In control rats, the inhibition of PGC-1
expression did not modulate glucose clearance rates during the clamp.
|
blockade reduces GLUT4 expression in membrane fraction independently of IR and Akt functional status.
Antisense oligonucleotide blockade of PGC-1
produced no significant modulation of basal (not shown) and insulin-induced tyrosine phosphorylation of the IR and of the Ser473 phosphorylation of Akt in type I (Fig. 7A)and type II (Fig. 7B) fiber-rich portions of gastrocnemius muscle. Nevertheless, blockade of PGC-1
expression significantly reduced the membrane expression of GLUT4 in type II (0.8-fold, P < 0.05; Fig. 7E) and type I (0.75-fold, P < 0.05; Fig. 7G) fiber-rich portions of gastrocnemius muscle from cold-exposed (Fig. 7, E and G), but not control (Fig. 7, D and F), rats. This effect was independent of whole muscle content of GLUT4 (Fig. 7C).
|
expression and AMPK activity.
AMPK is an intracellular fuel sensor that has recently been shown to play a role in the physiological control of insulin-independent glucose uptake (36). To evaluate the possible participation of AMPK in the mechanisms that regulate glucose uptake in cold-exposed animals, we initially performed immunoblot determinations of AMPK protein expression and AMPK Thr172 phosphorylation in type II and type I portions of gastrocnemius muscle. Cold exposure promoted a significant increase in Thr172 phosphorylation of AMPK in type II (2.8-fold, P < 0.05; Fig. 8A,bottom blot) and type I (3.4-fold, P < 0.05; Fig. 8B, bottom blot) fiber-rich portions of gastrocnemius muscle without affecting AMPK protein expression (Fig. 8, A and B, top blots). The inhibition of PGC-1
expression with PGC-1
antisense oligonucleotide, as well as the inhibition of AMPK activity by in vivo treatment with ARA-A, significantly reduced cold-induced Thr172 phosphorylation of AMPK in type II (0.4- and 0.3-fold for antisense and ARA-A treatments, respectively, P < 0.05) and type I (0.3- and 0.2-fold for antisense and ARA-A treatments, respectively, P < 0.05; Fig. 8, bottom blots) fiber-rich portions of gastrocnemius muscle but did not affect AMPK protein expression (Fig. 8, top blots). To evaluate the participation of phospho-Thr172 AMPK in glucose uptake during a hyperinsulinemic-euglycemic clamp, we treated control and cold-exposed rats with ARA-A and performed clamp studies. ARA-A was capable of significantly reducing control (0.4-fold, P < 0.05) and cold-induced (0.3-fold, P < 0.05) glucose consumption (Fig. 8C).
|
| DISCUSSION |
|---|
|
|
|---|
The high adrenergic tonus generated by exposure of homeothermic animals to cold is thought to play a central role in the control of glucose uptake driven by insulin-independent mechanisms (20, 21). This fact is reinforced by the demonstration of the antidiabetic effect of
3-adrenergic compounds such as CL-316243 (17, 21) and BRL-26830A (34). However, the molecular mechanisms by which the adrenergic stimulus improves glucose uptake independently of insulin action through the IR-IRSs-Akt pathway are not known. Studies concerned with the possible direct cross talk between insulin and
-adrenergic intracellular signaling systems have shown that insulin is able to induce tyrosine phosphorylation of residues at the COOH terminus of the
2-adrenergic receptor (12), whereas a
-adrenergic stimulus inhibits insulin signal transduction (15, 26, 47). As a rule, most of the sympathetic signals are thought to be deleterious for insulin signaling and participate negatively in the pathogenesis of diabetes mellitus (33). However, after the characterization of the
3-adrenergic receptor, it became clear that sympathetic inputs could play dual roles in this complex scenario (9).
Along with the recent characterization of PGC-1
(31), the demonstration of its induction by cold-induced adrenergic stimulus (30), and its properties of controlling GLUT4 expression and glucose uptake by insulin-independent mechanisms (22), we decided to evaluate its possible participation in cold-induced modulation of insulin signaling in skeletal muscle of rats.
As expected, cold exposure promoted a significant increase of PGC-1
expression in type I and type II fibers of gastrocnemius muscle that was accompanied by an increase of UCP-3 expression. Because the main objective of the present study was to evaluate the effect of PGC-1
on insulin signal transduction, we decided to begin by determining whether an acute dose of insulin would exert any modulation on the expression of PGC-1
. As expected, the protein levels of PGC-1
were not affected by a single intravenous dose of insulin.
Next, we evaluated the effect of cold exposure on key steps of the insulin signal transduction machinery. As previously reported, exposure to cold promotes a tissue-specific modulation of insulin signaling (11). In skeletal muscle, there is an apparent impairment of the insulin signal transduction (11), which was confirmed here. Furthermore, we demonstrate that the phenomenon occurs similarly in type I and type II fibers of gastrocnemius muscle. Only the metabolic-related Akt pathway is affected by cold exposure, whereas the growth-related ERK pathway is preserved. Although during cold exposure the insulin-signaling machinery in muscle is impaired, an increase of basal and insulin-induced glucose uptake and of whole body glucose clearance is detected. This phenomenon seems to be mediated, at least in part, by an insulin-independent accumulation of GLUT4 in the membrane fraction of type II and type I fiber-rich portions of gastrocnemius muscle (11, 18). No modulation of GLUT1 expression occurs.
To evaluate the participation of cold-induced PGC-1
in glucose uptake, insulin signal transduction, and GLUT4 localization in muscle, we utilized an antisense oligonucleotide to PGC-1
that promoted a significant reduction of PGC-1
expression in both fiber types of skeletal muscle. This oligonucleotide has been utilized in previous experiments and provided reproducible and effective inhibition of PGC-1
expression (7). In Western blot experiments, we observed that not only was PGC-1
protein expression reduced, but the levels of UCP-3 were reduced as well. This was accompanied by a significant change in the coupling of mitochondrial respiration, reinforcing the property of the antisense oligonucleotide to inhibit PGC-1
expression and, consequently, modulate UCP-3 expression and activity. In a recent study, Fan and co-workers (10) demonstrated that the inhibition of PGC-1
transcriptional activity by hyperexpression and recruitment of p160 Myb binding protein reduces mitochondrial respiration. This effect was accompanied by reduced expression of cytochrome c and
-ATP synthase. UCP expression was not evaluated. In the present study, UCP-3 expression was evaluated to provide further validation for the property of the antisense oligonucleotide to inhibit PGC-1
expression. However, the results also further support a role for skeletal muscle UCP-3 in thermogenesis, as recently described by Mills and co-workers (23), and evidence that, at least under cold exposure conditions, UCP-3 expression is controlled by the levels of PGC-1
. When PGC-1
expression was inhibited by the antisense oligonucleotide treatment, glucose uptake during the clamp was reduced and GLUT4 migration to the membrane fraction of muscle was significantly impaired. This close connection between PGC-1
expression levels, GLUT4 distribution, and glucose clearance strongly suggests that PGC-1
plays an important role in the whole body control of glucose disposal during cold exposure. Michael et al. (22) demonstrated that, in cultured myocytes that do not express GLUT4, the adenoviral-mediated hyperexpression of PGC-1
induces GLUT4 expression with a preferential localization in the cell membrane. Previous studies found a direct relation between uncoupling and GLUT4 expression in cultured cells and muscle of living mammals (18, 43). Because under conditions that promote mitochondrial uncoupling there are increased cellular needs for energy, a physiological rationale for a parallel regulation of GLUT4 and UCPs may be proposed. According to our results, PGC-1
may play a pivotal role in the simultaneous control of GLUT4 and UCP-3 expression. Finally, because inhibition of PGC-1
did not modulate insulin-induced IR and Akt phosphorylation, we believe that PGC-1
affects glucose uptake through mechanisms other than the those dependent on classic insulin signaling through the IR-Akt signal transduction pathway.
AMPK is a trimeric enzyme present in membrane and cytosolic fractions of cells from several tissues (36, 46). It acts as a metabolic switch in insulin-sensitive and non-insulin-sensitive cells (14), favoring the shutdown of fatty acid synthetic pathways to control the waste of energy under stressful conditions. Recent studies have demonstrated that AMPK activation may participate in the control of glucose uptake by insulin-independent mechanisms (28, 35). In the present study, cold exposure did not modulate AMPK expression but significantly increased its phosphorylation in Thr172, a phenomenon closely related to its catalytic activity. When PGC-1
expression was inhibited in cold-exposed rats, no modulation of AMPK expression was observed, but a significant decrease of its Thr172 phosphorylation was determined. Furthermore, blockade of AMPK activity with the chemical inhibitor ARA-A mimicked the action of PGC-1
inhibition on glucose consumption during the hyperinsulinemic-euglycemic clamp.
Pharmacological and exercise-induced activation of AMPK has been reported to lead to stimulation of PGC-1
and UCP-3 protein expression (32, 38, 39, 50). Thus, according to current concepts, PGC-1
is a downstream target of AMPK. In the present study, we show that inhibition of PGC-1
expression modulates AMPK activity. Because the intracellular levels of AMP are among the most important physiological regulators of AMPK activity and because, in the present report, we show that PGC-1
increases mitochondrial uncoupling, it would be expected that intracellular levels of AMP would increase on PGC-1
activation and, therefore, promote a positive modulation of AMPK activity.
Thus, as a whole, this study shows that
50% of the cold exposure-induced increment of glucose consumption determined by the clamp method is reversed by the inhibition of PGC-1
expression and is associated with the modulation of expression and membrane localization of GLUT4. These effects are not related to the functional status of the IR and Akt but accompany AMPK activity. These data show, for the first time, the participation of PGC-1
in the control of glucose uptake by muscle during cold exposure and reinforce the role of AMPK in the modulation of glucose homeostasis through mechanisms that act independently of insulin-induced activation of the IR-IRSs-Akt pathway.
| GRANTS |
|---|
|
|
|---|
| FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
| REFERENCES |
|---|
|
|
|---|
coactivator-1-dependent uncoupling protein-2 expression in pancreatic islets of rats: a novel pathway for neural control of insulin secretion. Diabetologia 46: 15221531, 2003.[CrossRef][Web of Science][Medline]
coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to type II diabetes mellitus. Diabetologia 44: 22202226, 2001.[CrossRef][Web of Science][Medline]
3-adrenergic receptor. Science 245: 11181121, 1989.
: modulation by p38 MAPK. Genes Dev 18: 278289, 2004.
2-adrenergic receptors in response to insulin. J Biol Chem 267: 2601726022, 1992.
-adrenergic effects on insulin signaling and action in
3-adrenoceptor-deficient brown adipocytes. Am J Physiol Endocrinol Metab 283: E146E153, 2002.
drives the formation of slow-twitch muscle fibres. Nature 418: 797801, 2002.[CrossRef][Medline]
3-adrenergic agonist CL-316243 in obese Zucker-ZDF rats. Am J Physiol Regul Integr Comp Physiol 274: R1212R1219, 1998.
coactivator-1. Mol Cell 8: 971982, 2001.[CrossRef][Web of Science][Medline]
coactivator 1
(PGC-1
): transcriptional coactivator and metabolic regulator. Endocr Rev 24: 7890, 2003.
1-subunit of AMP-activated protein kinase affect enzyme activity and cellular localization. Biochem J 354: 275283, 2001.[CrossRef][Web of Science][Medline]
. Dev Cell 5: 7383, 2003.[CrossRef][Web of Science][Medline]
This article has been cited by other articles:
![]() |
E. R. Ropelle, J. R. Pauli, D. E. Cintra, M. J. S. Frederico, R. A. de Pinho, Líc. A. Velloso, and C.áu. T. De Souza Acute exercise modulates the Foxo1/PGC-1\#945; pathway in the liver of diet-induced obesity rats J. Physiol., May 1, 2009; 587(9): 2069 - 2076. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. W. Franks, R. J. F. Loos, S. Brage, S. O'Rahilly, N. J. Wareham, and U. Ekelund Physical activity energy expenditure may mediate the relationship between plasma leptin levels and worsening insulin resistance independently of adiposity J Appl Physiol, May 1, 2007; 102(5): 1921 - 1926. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Al-Regaiey, M. M. Masternak, M. S. Bonkowski, J. A. Panici, J. J. Kopchick, and A. Bartke Effects of Caloric Restriction and Growth Hormone Resistance on Insulin-Related Intermediates in the Skeletal Muscle J Gerontol A Biol Sci Med Sci, January 1, 2007; 62(1): 18 - 26. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-C. Hsieh, M. A. Choudhry, H.-P. Yu, T. Shimizu, S. Yang, T. Suzuki, J. Chen, K. I. Bland, and I. H. Chaudry Inhibition of cardiac PGC-1{alpha} expression abolishes ER{beta} agonist-mediated cardioprotection following trauma-hemorrhage FASEB J, June 1, 2006; 20(8): 1109 - 1117. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |